Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Birgit Lorenz & Knut Stieger. (2015) Retinopathy of prematurity: recent developments in diagnosis and treatment. Expert Review of Ophthalmology 10:2, pages 167-182.
Read now
Read now
Articles from other publishers (14)
Amirfarbod Yazdanyar, Charles L. Cai, Jacob V. Aranda, Eric Shrier & Kay D. Beharry. (2023) Comparison of Bevacizumab and Aflibercept for Suppression of Angiogenesis in Human Retinal Microvascular Endothelial Cells. Pharmaceuticals 16:7, pages 939.
Crossref
Crossref
Fatemeh Bazvand, Hamid Riazi-Esfahani, Ahmad Mirshahi, Alireza Khodabande, Hasan Khojastheh, Afsar Dastjani Farahani, Ramak Roohipourmoallai, Marjan Imani, Hooshang Faghihi, Nazanin Ebrahimi Adib & Mohammadreza Mehrabi Bahar. (2021) Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors. International Journal of Retina and Vitreous 7:1.
Crossref
Crossref
Venkateshnaidu Laveti, Divya Balakrishnan, Padmaja Kumari Rani, Ashik Mohamed & Subhadra Jalali. (2020) Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9. International Ophthalmology 40:12, pages 3539-3545.
Crossref
Crossref
Atsuko Kato, Yoshifumi Okamoto, Fumiki Okamoto, Makoto Saito, Yayoi Miyazono & Tetsuro Oshika. (2019) Short-term intraocular pressure changes after intravitreal injection of bevacizumab for retinopathy of prematurity. Japanese Journal of Ophthalmology 63:3, pages 262-268.
Crossref
Crossref
Ulrich Spandau & Sang Jin KimUlrich Spandau & Sang Jin Kim. 2019. Pediatric Retinal Vascular Diseases. Pediatric Retinal Vascular Diseases
257
261
.
Birgit Lorenz, Knut Stieger, Melanie Jäger, Christine Mais, Susann Stieger & Monika Andrassi-Darida. (2017) RETINAL VASCULAR DEVELOPMENT WITH 0.312 MG INTRAVITREAL BEVACIZUMAB TO TREAT SEVERE POSTERIOR RETINOPATHY OF PREMATURITY. Retina 37:1, pages 97-111.
Crossref
Crossref
Lisa V. Stottlemyer. 2017. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
491
501
.
Kay D. Beharry, Gloria B. Valencia, Douglas R. Lazzaro & Jacob V. Aranda. (2016) Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity. Seminars in Perinatology 40:3, pages 189-202.
Crossref
Crossref
T R Padhi, T Das, S Rath, L Pradhan, S Sutar, K G Panda, R Modi & S Jalali. (2015) Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I. Eye 30:3, pages 392-399.
Crossref
Crossref
Lisa V. Stottlemyer & Alan Polnariev. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
503
512
.
Anand Vinekar, Chaitra Jayadev, Shwetha Mangalesh, Anupama Kiran Kumar, Noel Bauer, Antonio Capone, Michael Trese & Bhujang Shetty. (2015) COMPARING THE OUTCOME OF SINGLE VERSUS MULTIPLE SESSION LASER PHOTOABLATION OF FLAT NEOVASCULARIZATION IN ZONE 1 AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY. Retina 35:10, pages 2130-2136.
Crossref
Crossref
Laura Pertl, Gernot Steinwender, Christoph Mayer, Silke Hausberger, Eva-Maria Pöschl, Werner Wackernagel, Andreas Wedrich, Yosuf El-Shabrawi & Anton Haas. (2015) A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLOS ONE 10:6, pages e0129383.
Crossref
Crossref
Michael A. Klufas & R. V. Paul Chan. (2015) Intravitreal Anti-VEGF Therapy as a Treatment for Retinopathy of Prematurity: What We Know After 7 Years. Journal of Pediatric Ophthalmology & Strabismus 52:2, pages 77-84.
Crossref
Crossref
. (2014) Bevacizumab. Reactions Weekly 1509:1, pages 9-9.
Crossref
Crossref